D-1293-2022 Class II Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-1293-2022 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Jul 18, 2022 and is designated Class II. Reason for recall: Failed dissolution specifications. The recall status is terminated (terminated Nov 22, 2022). Affected quantity: 9,600 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 3, 2022
Initiation Date
Jul 18, 2022
Termination Date
Nov 22, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9,600 bottles

Product description

Irbesartan Tablets, USP, 150mg, 90- count bottles, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-448-90

Reason for recall

Failed dissolution specifications.

Distribution pattern

Nationwide within the United States

Code information

Lot #: IB220023A, exp. date 08/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1293-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1293-2022. Report a data issue: hello@regdatalab.com.